Cardium Therapeutics has completed the second tranche of its previously announced registered direct offering consisting of an additional 1,656 shares of Series A convertible preferred stock for gross proceeds of approximately $1.7 million, bringing the total gross proceeds of the offering to approximately $4.0 million.
For a detailed description of the terms of the securities purchase agreement as well as the rights, privileges, and preferences of the Series A Convertible Preferred Stock, view CXM’s current report on Form 8-K here: http://dtg.fm/45Ml.
CXM is an asset-based health sciences and regenerative medicine company engaged in the acquisition and strategic development of products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization.
For more information, visit www.cardiumthx.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment